NCT04362748View on ClinicalTrials.gov

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions
Advanced Solid Tumors
Interventions
DRUG

AMG 256

AMG 256 administered as an intravenous (IV) infusion.

Trial Locations (11)

1200

Cliniques Universitaires Saint Luc, Brussels

2010

St Vincents Hospital Sydney, Darlinghurst

2050

Chris OBrien Lifehouse, Camperdown

3168

Monash Medical Centre, Clayton

9000

Universitair Ziekenhuis Gent, Ghent

46202

Indiana University, Indianapolis

63110

Washington University, St Louis

77030

University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

08035

Hospital Universitari Vall d Hebron, Barcelona

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT04362748 - Study of AMG 256 in Adult Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter